Illumina, Inc. $ILMN Position Increased by MAI Capital Management

MAI Capital Management boosted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 211.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 785 shares of the life sciences company’s stock after buying an additional 533 shares during the quarter. MAI Capital Management’s holdings in Illumina were worth $75,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of ILMN. Parkside Financial Bank & Trust grew its holdings in shares of Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 115 shares during the last quarter. Rise Advisors LLC boosted its position in shares of Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 224 shares during the period. Cullen Frost Bankers Inc. purchased a new position in Illumina in the 2nd quarter worth about $41,000. NewSquare Capital LLC raised its holdings in Illumina by 604.9% during the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after buying an additional 369 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Illumina by 2,936.8% during the first quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock valued at $46,000 after buying an additional 558 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Activity

In other news, Director Scott Gottlieb purchased 500 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was acquired at an average price of $122.13 per share, with a total value of $61,065.00. Following the purchase, the director owned 12,523 shares in the company, valued at $1,529,433.99. This represents a 4.16% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on ILMN. Cowen reissued a “hold” rating on shares of Illumina in a research report on Friday, October 31st. Daiwa Capital Markets cut shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective on the stock. in a research report on Tuesday, August 12th. UBS Group boosted their target price on shares of Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. raised their target price on Illumina from $100.00 to $105.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Finally, Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Five analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $115.00.

Illumina Trading Up 1.2%

Illumina stock opened at $131.39 on Friday. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $153.06. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The stock has a market cap of $20.08 billion, a P/E ratio of 16.63, a P/E/G ratio of 2.34 and a beta of 1.42. The company’s fifty day simple moving average is $107.97 and its 200-day simple moving average is $99.30.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the firm earned $1.14 earnings per share. The business’s revenue for the quarter was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.